Newsbenzinga
Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder
· Published
Article summary
Alterity Therapeutics advances ATH434 toward Phase 3 after FDA alignment on trial design for MSA, while shares decline in premarket trading.
An excerpt from the original article.
Comments —
Loading comments…